Print
Email
Print Edition StoriesTuesday, October 20, 2009
Aileron Therapeutics appoints Kafka as CFO
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
Protein-focused biotech company Aileron Therapeutics Inc. has named Steven Kafka as its chief financial officer and vice president of finance and operations. Kafka reports to Aileron CEO Joseph Yanchik III and will be responsible for directing the company’s corporate communications, strategic and operational finances, and human resources.
Kafka joins Aileron having previously worked for Infinity Pharmaceuticals Inc. as vice president, finance. While there, he helped Infinity land a deal, worth up to $500 million, with Purdue Pharma and Mundipharma. Other prior positions that Kafka held include senior director, finance, at Millennium Pharmaceuticals Inc., and senior engagement manager at Strategic Decisions Group.
Kafka graduated from Stanford University with a bachelor’s degree and from Harvard University with a Ph.D.
Aileron is developing therapies using small pieces of a naturally occurring protein, called Stapled Peptides, that restore programmed cell death in multiple myeloma cells.
In June, the company closed on $40 million in a fourth round of financing that was co-led by new investors SR One Ltd., the corporate venture fund of GlaxoSmithKline (NYSE: GSK), and Excel Medical Fund. The Series D round also included existing investors Apple Tree Partners — the founding investor of Aileron — and Novartis Venture Fund, Lilly Ventures and Roche Venture Fund.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.